Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 14/20 | 0.54 |
| ▸ | KDR | P35968 | 6/20 | 0.47 |
| ▸ | LCK | P06239 | 2/20 | 0.47 |
| ▸ | FYN | P06241 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 2/20 | 0.47 |
| ▸ | LYN | P07948 | 2/20 | 0.47 |
| ▸ | KIT | P10721 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 2/20 | 0.47 |
| ▸ | FLT1 | P17948 | 2/20 | 0.47 |
| ▸ | FLT4 | P35916 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 2/20 | 0.47 |
| ▸ | BLK | P51451 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6115984 | 0.87 | BTK (0.51) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6115425 | 0.83 | BTK (0.67) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6116270 | 0.77 | BTK (0.55) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL8401672 | 0.77 | BTK (0.57) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6115759 | 0.77 | BTK (0.65) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6115976 | 0.76 | BTK (0.61) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6116012 | 0.76 | BTK (0.57) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL5555113 | 0.76 | JAK2 (0.55) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL1162998 | 0.75 | BTK (0.69) | BTKKDRLCKFYNCSF1R | |
| SCHEMBL6115914 | 0.74 | BTK (0.57) | BTKKDRLCKFYNCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | claimed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | claimed |
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2789615-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789615-A1 | Azaindazoles as Btk kinase modulators and use thereof | Bristol-Myers Squibb Company (US) | 2014-10-15 | — | — | EP | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846673-B2 | Azaindazoles as kinase inhibitors and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2012-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120129852-A1 | AZAINDAZOLES AS KINASE INHIBITORS AND USE THEREOF | BTK, ABL1, JAK1 | BTK 1/4885KDR 476/4885LCK 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.